key: cord-0957568-4twsg9t8
authors: Cheng, YunFeng; Li, MinYong; Wang, ShaoRu; Peng, HanJing; Reid, Suazette; Ni, NanTing; Fang, Hao; Xu, WenFang; Wang, BingHe
title: Carbohydrate biomarkers for future disease detection and treatment
date: 2010-02-07
journal: Sci China Chem
DOI: 10.1007/s11426-010-0021-3
sha: 529a7729c68a3026a4682e09c74a1b2aa72a95fb
doc_id: 957568
cord_uid: 4twsg9t8

Carbohydrates are considered as one of the most important classes of biomarkers for cell types, disease states, protein functions, and developmental states. Carbohydrate “binders” that can specifically recognize a carbohydrate biomarker can be used for developing novel types of site specific delivery methods and imaging agents. In this review, we present selected examples of important carbohydrate biomarkers and how they can be targeted for the development of therapeutic and diagnostic agents. Examples are arranged based on disease categories including (1) infectious diseases, (2) cancer, (3) inflammation and immune responses, (4) signal transduction, (5) stem cell transformation, (6) embryo development, and (7) cardiovascular diseases, though some issues cross therapeutic boundaries.

Carbohydrates, traditionally considered as bioenergy suppliers and structural components, have been found to have a wide variety of biological and physiological functions. Therefore, together with proteins and peptides, nucleic acids and oligonucleotides, and lipids, carbohydrates are considered one of the most important classes of biomacromolecules [1] [2] [3] [4] . In addition, the relationship among these four classes of biomolecules is often intertwined. For example, protein glycosylation is very important to its conformation, transportation, function, and fate [5-16]; glycosylated lipids (glycolipids) are essential biomolecules [3, 17-22]; and nucleic acid glycosylation, whether synthetic [23] or natural [24] [25] [26] [27] [28] [29] [30] [31] , has recently been recognized as important in affecting its distribution and function. Because of all these properties, it is not surprising that carbohydrates are biomarkers for cell types, disease states, protein functions, and developmental states [2, 32-40]. Recent years have seen a rapid increase in knowledge related to all these areas mentioned. Such advancements can largely be attributed to the development in new techniques, such as NMR and mass spectrometry, and molecular biology, and the ready availability of genomic information. As a result, recent advancements in glycobiology and glycomics have also opened new doors for the development of new therapeutics and imaging agents through carbohydrate recognition. Therefore, compounds that can specifically recognize a particular carbohydrate have very important applications [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . They can be used as sensors for detection, diagnosis, and prognosis, as "blockers/inhibitors" for therapeutics development if the target carbohydrate is involved in pathogenesis, and as vectors for the targeted delivery of imaging and therapeutic agents. Critical to all these potential applications are two issues: (1) the identification of carbohydrate biomarkers and (2) the design and synthesis of "binders" that can specifically recognize the target biomarker with high affinity and specificity. In this review, we present selected examples of important carbohydrate biomarkers and how they can be targeted for the development of therapeutic and diagnostic agents. It should be noted that there are many books on glycobiology and there are many review articles on how one can target carbohydrates for various applications [45, 51, [53] [54] [55] and it would be impossible to cover the entire topic in detail. Therefore, this article does not strive to be comprehensive. Instead, it is meant to be "tutorial," which we hope would help to generate more interests in carbohydrate recognition as a way for the development of new therapeutics and diagnostics. Carbohydrate recognition research impacts essentially all areas in which carbohydrates play a role. Examples include (1) infectious diseases, (2) cancer, (3) inflammation and immune responses, (4) signal transduction, (5) stem cell transformation, (6) embryo development, and (7) cardiovascular diseases. In the following sections, we divide the discussions based on disease categories though some issues cross therapeutic boundaries. In the last section, we present a few simple examples of how to target carbohydrate biomarkers for diagnostic and therapeutic applications.

Among all pathologically relevant glycosylation changes, cancer is probably the most extensively studied. Even in normal cells, surface carbohydrate structures are known to be characteristic markers for different types of cells [56] [57] [58] [59] [60] [61] . Transformations of normal to cancerous cells are often associated with the alteration of cell surface carbohydrates and the expression or over-expression of certain carbohydrates has been closely correlated with cancer [56] [57] [58] [59] [60] [61] . Therefore, many carbohydrates are considered cancer associated antigens (CAA). Among all carbohydrate-based CAA, Globo H and the Tn antigen are probably the most common. It is known that the Tn antigen is found on the cell surface of over 90% of solid tumor [62] . The formation of the Tn antigen is because of deficiency of an enzyme named β-1,3-galactosyltransferase, which results in the incomplete conversion of the Tn antigen to the T antigen. Other important cancer-related carbohydrates include the sialylated carbohydrates. For example, sialyl Lewis X (sLe x ) has been shown to mediate lung colonization of B16 melanoma cells [63] and yet excessive sLe x expression is shown to lead to rejection by natural killer cells [64] ; serum sLe x and cytokeratin 19 fragment are said to be predictive factors for recurrence in patients with stage I non-small cell lung cancer [65] ; and sLe x and sialyl Lewis a (sLe a ) have been shown to mediate adhesion of urothelial cancer cells to activated endothelium [66] . Changes in sLe x and sLe a levels in cancer have been attributed to both "neosynthesis" and "incomplete synthesis" of pathways involving sulfation or sialylation [67] and variations of enzyme levels can be directly correlated with certain changes in glycosylation [68] . With all these aberrant glycan expressions, "binders" that can recognize these carbohydrates will be very useful research tools, diagnostic agents, and possibly therapeutic agents [51] .

In addition to cell surface carbohydrate biomarkers, post-/co-translational protein glycosylation often carries signatures of malignant transformations . In terms of the biological significance of protein glycosylation, usually it is not a question of whether there is glycosylation; rather it is the glycosylation pattern that marks different pathological states including malignancy. For example, the glycosylation patterns of prostate specific antigen (PSA) from cancer cells in culture [94] and prostate cancer patients' tissue and sera [69, 93, 95] are different from that of normal prostate; human pancreatic RNase 1, a glycoprotein secreted mostly by pancreatic cells, has completely different oligosaccharide chains when produced from pancreatic tumor cells [39, 71, 96, 97] ; pregnancy-related human chorionic gonadotropin (hCG) can be biomarkers for cancer, Down syndrome, and pregnancy failure depending on their glycosylation patterns [98, 99] ; and specific glycosylation patterns of haptoglobin (Hp) and alpha-fetoprotein (AFP) have a much higher degree of correlation with cancer than the total Hp/AFP levels [100, 101] . In such cases, "binders" that can recognize glycosylation variations can be very useful diagnostic tools.

There are several ways in which carbohydrates are involved in the pathogenicity of infectious agents. In the case of viral infections, the human influenza virus is an excellent example. Flu viral infection involves sialic acid for binding to hemagglutinin and infection. After infection, the budding of mature viruses from infected cells involves the cleavage of sialic acid by neuraminidase in order for the virus to detach [102, 103] . Flu drug such as tamiflu functions by inhibiting neuraminidase and thus inhibit viral replication [104, 105] .

In the case of human immunodeficiency virus (HIV), a critical protein, gp120, is glycosylated with polymannose [106, 107] . Infection of cells by HIV-1 requires the fusion of the viral membrane with cellular membrane [108] . This fusion is mediated by gp120 and gp41 along with cell surface receptors (CD4 and chemokine receptor) on the target cells [109] . Conceivably, agents that interact with gp120 may interfere with viral entry into target cells [110] . Binding to glycans on the viral envelope may also force the virus to delete a portion of its glycan shield, making the virus more susceptible to attack [111] . Along this line, several lectins have been studied for their anti-HIV activities. For example, cyanovirin-N (CV-N) is a 11kDa protein with 101 amino acids and has affinity for high-mannose glycans especially α-(1,2)-linked mannose oligomers [112, 113] . CV-N inactivates T-lymphocyte-tropic, laboratory strains of HIV type 1 and HIV type 2, as well as T-tropic, M-tropic and dual tropic primary clinical isolates of HIV-1, presumably through inhibition of viral entry by blocking part of gp120. In CEM-SS cells, CV-N has an EC 50 of 0.1 nM. As a control, treatment of uninfected CEM-SS cells in the presence of high concentrations (9000 nM) of CV-N did attenuate the lethal effect of the virus. Other lectins have also shown similar effect, presumably by binding to the polymannose portion of gp120. These include SVN (scytovirm), which has affinity for α(1,2)-α(1,6)-mannose trisaccharide units and can inhibit HIV infection in T-tropic laboratory strain HIV-1 in CEM-SS cells with an EC 50 of 0.3 nM [114] , and actinohivin, which has affinity for mannose-type glycans [115] and can inhibit T-cell and macrophage infection by HIV-1 in cell culture (IC 50 of 60 to 700 nM). All such results indicate that the viral envelope glycans play an important role in their pathogenicity.

In bacterial pathogenicity, carbohydrates also play very important roles. One prominent example is lipopolysaccharides (LPS), also known as endotoxin, from the outer membrane of cell wall of Gram negative bacteria. One such example is Pasteurella multocida, an encapsulated, Gramnegative coccobacillus that causes a wide range of animal diseases including avian fowl cholera [116] . When infections by Gram-negative bacteria occur, LPS stimulate the immune system in an attempt to clear the bacteria and the infection that may result. The lipid A component of LPS is primarily responsible for this inflammatory response. As the infection proceeds, the presence of a large amount of LPS can result in an overproduction of inflammatory mediators that result in damage to tissues, septic shock, organ failure, and death [117] . LPS has also been shown to play an important role in the pathogenesis of P. multocida, in which modification of LPS structure negatively affects the viability of P. multocida in vivo [118] . In addition to functioning as toxins, carbohydrates can also be the target for bacterial recognition. For example, many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids [119] ; Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gan-gliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2) [120] ; the pili of P. aeruginosa strains PAK and PAO bind specifically to the carbohydrate sequence beta GalNAc(1-4)beta Gal found in glycosphingolipids asialo-GM1 and asialo-GM2 [121] ; adherence of P. aeruginosa and Candida albicans to glycosphingolipid (Asialo-GM1) receptors is achieved by a conserved receptor-binding domain present on their adhesions [122] ; lactoand ganglio-series glycolipids are adhesion receptors for Neisseria gonorrhoeae [123] ; and there are many other examples [124] . In addition to all these, serotyping of Gram-negative bacteria is primarily based on their LPS structures [125] . Because of the many ways that carbohydrates can affect bacteria (and fungi) infections, one can envision situations where artificial "binders" of the target carbohydrates can be used for detection and treatment of bacterial and fungal infections.

Carbohydrates are involved in mediating inflammatory processes in many ways. The most widely known example is probably sLe x -mediated white blood cell adhesion to infection/damaged sites through interactions with L-selectin. Recent studies unveiled that 6-O GlcNAc sulfate modification of the sLe x tetrasaccharide is of importance in Lselectin activity in animal and in leukocyte invasion into different human tissues [126] . Furthermore, the de novo induction of endothelial sLe x or its sulfated form through interactions with L-selectin is a common event in many organs, including thyroid gland, heart, skin and colon, thus, suggesting a crucial role for these glycans in the early-state induction of tissue inflammation [127] .

The most prominent examples of carbohydrate-mediated immune responses originate from the ABO blood group antigens, which are entirely carbohydrate-based [128] . Figure 1 shows the structures of these antigens. The difference between the A and B blood types is due to their terminal galactosamine N-acetylation on red blood cells, while type O antigen lacks the terminal sugar. Therefore, persons of one blood type, such as A, would have natural antibodies against the other type (such as B) by targeting the difference in the terminal sugar structures. However, since O-type antigen does not have the terminal sugar and only has the common sugar structure, no antibody against the common core is produced by individuals of any blood type, which is the reason that O-type is "universal" [129] .

Another type of carbohydrate-mediated immune response is the natural immunity in human against animal tissues. For example, pig cell surface has an antigen including the α-Gal-Gal moiety [130] , which is absent on human cells. Therefore, humans have natural antibodies against α-Gal-Gal [131] . The acute immune response against α-Gal-Gal is a major hurdle in organ transplant using pig organs. A few years ago, genetically engineered pigs were produced [132, 133] , which lack the α-Gal-Gal moiety and thus allow for organ transplant using pig organs to move one step closer to reality. In addition, targeted delivery of the α-Gal-Gal moiety has also been used to elicit immune response at a specific location or cell type [134] .

Fundamentally, stem cell differentiation and embryo development are the same. The process of transforming pluripotent stem cells into those of specialized functions is marked by different stages, which have characteristic stage-specific biomarkers. Such biomarkers are often carbohydrate-based [135] [136] [137] and can be targeted in "binder" development for various applications [138] . For example, Lewis X (Le x ) has been identified as a stage-specific embryonic antigen, which can be used for identifying and isolating specific cell types from heterogeneous populations [139, 140] . Along this line, it was reported that sorting SVZ cells on the basis of Le x was a good strategy to enrich a restricted but highly proliferative neutral stem cell population [141] . Other examples of carbohydrate changes at various developmental stages include (1) enriched fucose incorporation into macromolecules was found on cell surface at the 8-to 16-cell stage in pre-implantation mouse embryos [142] ; (2) sialic acid was found on the 12th day of incubation of metanephros while before that time only N-acetyl-D-glucosamine and alpha-D-mannose were found to exist ubiquitously [143] ; (3) in chick embryo development, glycopeptides were found to be mainly N-linked on the 8-day and both O-and N-linked on the 16th day with increased sialylated small glycopeptide contents [144] ; and (4) glycosylation of two identical polypeptide chains was found to be organ specific by analysis of chicken serum transferrin and ovotransferrin glycans [145] . There are also many other examples of these biomarkers, such as SSEA-1, -3, and -4 and tumor rejection antigen (TRA)-1-60 and -1-81 [137, 139, 146] . All such results indicate that carbohydrate biomarkers play very important roles in the stem cell differentiation and embryo development. In stem cell research, one critical element is the ability to purify cells of the same differentiation stage and lineage. "Binders" that can recognize stage-specific biomarkers will be very useful for the purpose of separation and identifications. Along this line, aptamers can be very useful since their selection does not require prior knowledge of the nature and structure of the biomarkers in questions. There have been successful examples of selecting aptamers for cell-surface biomarkers using whole cells for the selection [138, [147] [148] [149] [150] [151] . For example, liver cancer-specific aptamers were developed by using whole live cells [152] . This study demonstrates that cell-based aptamer selection can specifically recognize cells from multiple cell lines, even for two cell lines with minor differences [152, 153] . In another study, a series of aptamers were selected for leukemia cells. These aptamers have dissociation constants (K d ) in the nano to pico-molar range. The selected aptamers could specifically recognize leukemia cells when mixed with normal human bone marrow aspirates. These aptamers were also used to identify cancer cells closely related to the target cell line in real clinical specimens [154] . Therefore, cell-based selection is a very promising method of developing specific molecular probes for cell-surface biomarker recognition. Similar approaches can be applied to stem cells for the selection of aptamers capable of recognizing stage-specific carbohydrate biomarkers. The recent development of boronic acid-modified DNA-based aptamers [155] allows for the selection of high affinity "binders" for glycoproteins with the ability to differentiate variations in glycosylation patterns and should tremendously enhance the chance of finding high affinity aptamers for such cell-surface carbohydrate biomarkers because of the intrinsic affinity of the boronic acid moiety for carbohydrates [51, 55] . Recently, the Schultz lab has developed a way of engineering boronic acid-modified protein [155, 156] . This will also be very useful in selecting artificial lectins for carbohydrate recognition.

In the signal transduction area, the most prominent example is probably with glycosphingolipids (GSLs), which are involved in a whole host of activities. GSLs have the general structure of two hydrophobic tails (ceramide, consisting of Sph and fatty acid) and one carbohydrate chain, which are oriented perpendicularly. GSLs are held in the membrane by ceramide such that the carbohydrate chain is accessible to various ligands (antibodies, lectins, and complementary carbohydrates) (Figure 2 ) [157] . GSLs are an integral part of cellular membrane, which functions as antigens, receptors for microbial toxins, and mediators of cell adhesion and modulators of signal transduction. Many functions were attributed to the unique property of GSLs to form clusters. Glycosynapse refers to glycosphingolipids-enriched microdomain, and glycosynaptic domains, which control GSLdependent or -modulated cell adhesion, growth, and motility, are formed by the interaction of GSL clusters and functional membrane proteins. Modulation of glycosynapse functions can lead to new strategies in cancer therapy, and elucidation of the molecular mechanism of interaction among components in glycosynaptic domain might shed lights on new possible approaches to disrupt or promote such interactions [119, 121, 122, [157] [158] [159] [160] [161] .

Protein glycosylation is known to be involved in regulating signal transduction as well. For example, the dynamic glycosylation of serine or threonine residues on nuclear and cytosolic proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) has been implicated in regulating protein-protein interaction(s) and/or protein function [162] ; the Notch signaling pathway could be regulated by alterations of Ofucose structures [68] ; O-fucose modification of Cripto is essential for Nodal-dependent signaling [68] ; glycosylation of human CRLR at Asn123 is required for ligand binding and signaling [163] ; elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation [164] ; alternative O-glycosylation/O-phosphorylation of serine-16 regulates the activities of murine estrogen receptor beta [165] ; NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions [166] ; glucose deprivation stimulates O-GlcNAc modification of proteins through upregulation of O-linked N-acetylglucosaminyltransferase [167, 168] ; a mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin [169] ; O-glycosylation of Sp1 by insulin seems to enhance its nuclear recruitment and results in activation of CaM gene transcription [170] ; and glycosylation of guanylyl cyclase C affects its conformation and functional ability [134] . There are many other reports of similar nature.

In 1993, a uniquely glycosylated base, β-D-glucopyranosyloxymethyluracil (also called base J), was identified in the nuclear DNA of Trypanosoma brucei [171] . This is a rare, if not the only, case where DNA glycosylation is known to play a very important physiological role in signal transduction and gene silencing [24, 25, 27, [172] [173] [174] [175] . Specifically, base J is said to be the first hypermodified base found in eukaryotic DNA in the telomeric repeats and to be present in all kinetoplastid flagellates analyzed and some unicellular flagellates closely related to trypanosomatids [176] . In one study, Sabatini and coworkers proposed a model in which chromatin remodeling by J Binding Protein (JBP2) regulates the initial sites of J synthesis within bloodstream form trypanosome DNA, with further propagation and maintenance of J by JBP1. Synthesis of J within telomeric DNA of Trypanosoma brucei correlates with the bloodstream-formspecific epigenetic silencing of telomeric variant surface glycoprotein genes involved in antigenic variation [177, 178] . All such results suggest that binding and modulation of glycans of various proteins, lipids, and even DNA may allow for regulation of signal transductions.

In the cardiovascular area, the case of glycosylated hemoglobin (technically it should be glycated since the attachment of a sugar moiety is through chemical reactions) is most widely recognized. Specifically, glycated hemoglobin (GlcHb) level is a strong indicator of cardiovascular disease (CVD) risk in diabetic patients [179] [180] [181] [182] [183] [184] , who die of CVD at rates 2-4 times higher than those without diabetes [181] . In vivo, glycation, normally defined as a nonenzymatic reaction of glucose with amino groups in protein to form the Amadori product [185] (Scheme 1), is generally considered the first step in the Maillard reaction [186, 187] . Later stages of Maillard reaction lead to the formation of sugar-derived protein adducts and advanced glycation end-products (AGEs), which play an important role in the pathogenesis of chronic diseases [182] . The term GlcHb generally refers to the full spectrum of glycated hemoglobins, including those containing glycated valine (such as HbA 1c ) and/or lysine residues. In a normoglycemic person, GlcHb accounts for ~24% of total hemoglobin at the end of the erythrocyte lifespan (~120 days), including 4% HbA 1c [182, 188] . However, elevated glucose concentration in diabetic patients significantly increases this glycation reaction. For example, some diabetic patients have about 2-4 fold increases in HbA 1c [189] . Although certain important questions regarding the prevention of CVD in diabetic patients remain unresolved, epidemiologic analyses suggested that a 1% increase in glycated hemoglobin elevates the risk for CVD by approximately 18% [181] .

Another example of glycosylation's effect on cardiovascular diseases is with fibrinogen, which circulates in the blood as the precursor of fibrin, the structural component of blood clot. It plays a key role in platelet aggregation, the final step of the coagulation cascade, and is a major deter-Scheme 1 Reaction between glucose and the amino group of a protein to form the Amadori product. minant of plasma viscosity and erythrocyte aggregation [190] . Fibrinogen is a glycoprotein with a molecular weight of 340 kDa [191] and contains approximately 3% carbohydrate consisting of NeuAc, Gal, Man, and GlcNAc [192] . From amino acid sequence studies, it has been determined that carbohydrate is linked to Asn52 on the γ chain and Asn364 on the Bβ chain [193, 194] . The carbohydrate moieties play important roles in fibrinogen functions [195, 196] and are involved in the clotting process, although some contradictory results have been reported [197] [198] [199] : deglycosylated fibrinogen could accelerate polymerization and increase lateral aggregation of fibrin fiber [200] ; the desialylated oligosaccharide chains of fibrinogen could potentially mediate plasma clearance via the hepatic galactose/ galactosamine binding lectin [201] ; altered amounts of carbohydrate in fibrinogen are known to be directly related to certain types of dysfibrinogenemia [202] ; extra negative charges (sialic acids) on fibrinogen can impair fibrin polymerization [203, 204] , presumably due to the repulsive forces of the charges; and steric hindrance presented by additional glycan structures can also impair fibrin polymerization [203] . Fibrinogen-related abnormality is also implicated in other diseases such as hepatoma [202] , pancreatic [33, 205] and other cancers [33, [206] [207] [208] [209] [210] [211] [212] [213] , tumor metastasis [208, [214] [215] [216] , human hemopoietic cell proliferation [217] , and embryogenesis and reproduction [218] . Some of these pathological changes are directly related to abnormal glycosylations [203, 204, [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] . In addition, there are many other situations where glycosylation affects the health of the cardiovascular system. For example, certain congenital disorder of glycosylation has been linked to intracranial hemorrhage [229] .

The above examples are far from a complete list and are at best some highlights of examples where glycosylation variations play an important role in determining the biological outcome. However, even from this incomplete list, it can be seen that "binders" that can recognize a carbohydrate biomarker with high specificity and affinity would have great application potentials as sensors for concentration analysis, diagnostics, and possibly therapeutic agents. Be-low is a section describing the general concept of artificial "binder" design. It should be noted that there are several extensive reviews and book chapters on this subject. The following section is far from comprehensive. It can only be treated as some basic conceptual description. Readers are referred to published reviews [45, 51, 54, 55, 230, 231] and book chapters [232, 233] for more details.

As discussed above, "binders" that can recognize certain carbohydrates with high affinity and specificity should be very useful research tools and potential diagnostic and therapeutic agents. However, achieving high affinity and high specificity carbohydrate recognition is not a trivial issue. In molecular recognition, antibody is often the gold standard. However, in the case of carbohydrates, raising antibodies is often a difficult task. More often than not, low affinity IgM antibodies are obtained. Recently, Boons [234] and colleagues have developed a remarkable synthetic approach to carbohydrate-protein conjugates, which elicits strong immune responses with very high titer. Naturally occurring protein "binders" include lectins [235, 236] . A few hundreds of lectins have been identified, about 60 of which are commercially readily available. Lectins all have certain specificity based on the overall topology and sugar compositions. For example, there are lectins that recognize polymannose structures and others that can recognize galactose connected to different structures. However, essentially all lectins have cross reactivity issues [237, 238] .

Recent years have seen a great deal of interest in developing artificial lectins for various applications. These artificial lectins can generally be divided into two types: boronic acid-based and non-boronic acid based. The reason that boronic acid plays such an important role is that it can form tight complexes with diol-containing compounds. Sometimes single hydroxyl group interactions are sufficient in reinforcing highly specific macromolecular interactions. All these aspects have been discussed in detail in a recent re-view and will not be duplicated here [51] . One thing that needs to be emphasized is the misperception that boronic acids only interact with linear diols and diols on fivemembered ring. There are ample literature precedents demonstrating that boronic acid interactions with single hydroxyl groups or other nucleophiles/Lewis bases can also play a very important role in designing/selecting carbohydrate "binders" [51] . Since all boronic acid-containing carbohydrate "binders" function in a similar fashion as lectins, we have termed them as boronolectins [55] . Within the boronolectin category, there are small molecule-and macromolecule-based boronolectins including boronic acid-based carbohydrate sensors [51, 55, 239] , nucleic acid-based boronolectins (NABL) [240] , peptide boronolectins (PBL) [241] [242] [243] [244] , and protein boronolectins (PrBL) [155, 156] . Each of these categories is discussed briefly below.

In this approach, the design is mostly based on hydrophobic and hydrogen bond interactions for recognition. Though early efforts were mostly on recognition in organic solvent, recently there has been remarkable progress in making noncovalent carbohydrate binders which showed reasonably high affinity in water, especially those by the Davis lab [245] [246] [247] [248] [249] . One example comes from the successful design of such a binder (1, Figure 3 ) for all-equatorial disaccharides, such as D-cellobiose, with good affinity and selectivity in aqueous solution [248] . Receptor 1 has two building blocks: (1) a-meta-tertphenyl structure providing the "roof" and "floor" for hydrophobic interactions with carbohydrates and defining the length of the binding cavity; (2) isophthalamide units serving as pillars, with the potential to form hydrogen bonds, promote solubility, as well as prevent the cavity from collapsing. The binding constants between reporter 1 and selecting carbohydrates were determined to be 

Recently, Boons and Davis reported another analog 2 (Figure 4) using the same design concept, with a biphenyl "roof" and "floor" as well as isophthalamide "pillars" [249] . In a previous study, receptor 2 showed weak bind for the β-glucosyl unit (K a = 9 M −1 for D -glucose (α/β = 40/60) and 5 M −1 for D-glucose (α/β = 72/28); K a = 27 M −1 for methyl-βglucoside and 7 M −1 for α-anomer) [247] . In an expanded study, 2 was recently reported as a strong and selective receptor for β-GlcNAc. The apparent binding constant between GlcNac β-OMe (Figure 4) and receptor 2 was determined to be 630 M −1 , which competes well with one lectin (WGA, K a = 730 M −1 ). Furthermore, receptor 2 has higher selectivity for GlcNac β-OMe than for the α-anomer and other N-acetylaminosugars.

Among all the carbohydrate sensors, boronic acid emerges as the most commonly used functional group for recognition, due to its strong interactions with diols [51- 55, 231, 239, [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] , aminoalcohols [264] [265] [266] , α-aminoacids [267] , α-hydroxyl acids [268] [269] [270] [271] , alcohols [55, 233, [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] as well as cyanide [288, 289] and fluoride [290] [291] [292] [293] [294] . The intrinsic ability for boronic acids to interact with nucleophiles is described in Scheme 2. The boron atom has only 6 valence electrons in its trigonal neutral form, which makes boronic acid a Lewis acid and capable of strong interactions with Lewis bases/nucleophiles. As a result, the boronic acid (3, Scheme 2) group is able to react with a protic solvent and convert to its anionic tetrahedral form (4). Both 3 and 4 are able to form tight and reversible complexes with 1,2and 1,3-substituted Lewis base donors such as hydroxyl, amino, and carboxylate groups. Several factors such as O-C-C-O dihedral angle, pK a values of the diol, buffer, ionic strength, as well as solvent all affect the complexation [55, 295, 263, 296] .

Small molecule boronolectins (SBLs) have drawn a great deal of attentions in carbohydrate biomarker recognition and targeting [51] . Several recent reviews and research papers comprehensively summarize the use of boronic acids in sensor designs for carbohydrates [51, 54, 55, 231, 239] fluoride [290] [291] [292] [293] [294] , cyanides [288, 289] , as well as in-depth discussions of factors [55, 263, 296] that should be considered along the line of designing such sensors. Besides, there have also been quite a few recent reviews [51, 53] and research papers [44, 156, [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] [311] [312] on boronic acids that change fluorescent properties upon binding to a nucleophilic analyte or pH changes. Readers are referred to the above-referenced papers for details. Below, several representative examples are discussed to highlight applications. One such example comes from the Wang lab, which developed an anthracene-based diboronic acid compound for sialyl Lewis X (sLe x ). The anthracene-based boronic acid was first developed by the Shinkai group [253] , whose fluorescence can be quenched by nitrogen lone pair electrons and recovered if lone pair electrons are masked through protonation after binding with carbohydrates [140] . By taking advantage of this, Wang and co-workers successfully designed and synthesized a series of anthracene-based diboronic acid compounds with different linkers, rigidity, and spatial orientation for recognition of sLe x on cell surface [254, 313] . Among all the designed compounds, sensor 7 ( Figure 5 ) stands out as an excellent receptor, which was able to label sLe x -expressing cells at low concentrations (0.5 μM) without cross-reactivity to Ley-expressing cells. This represents the first example of a small organic molecule used to fluorescently label cells based on the cell-surface carbohydrate structures. Further development along this line could lead to a number of small molecule boronolectins for labeling, drug delivery, and selective imaging applications.

In another example, the Hall lab in 2006 reported an orthohydroxymethyl phenylboronic acid (8, Scheme 3), which competes well with the well-established dialkylamino (Wulff-type) analogs with better binding affinity and solubility [272, 306] . The most significant finding of compound 8 was the weak but encouraging binding with model glycopyranosides. In aqueous media at physiological pH (7.4), the apparent binding constant between 8 and methyl α-Dglucopyranoside was determined to be 22 M −1 , which was slightly lower than that for glucose (K a = 36 M −1 ). This system has been used by the Hindsgaul lab for the detection of the terminal glycosylation of a glycoprotein with the aid of colored ortho-hydroxymethyl phenylboronic acid conjugates [314] .

Scheme 3 Binding between ortho-hydroxymethyl phenylboronic acid 8 and glycoconjugates.

Another area developed recently in carbohydrate sensor design is nucleic acid-based boronolectins (NABL). The Wang lab is working on incorporating boronic acid-modified thymidine into DNA for aptamer selection work for glycoproteins. A boronic acid-labeled thymidine triphosphate (BTTP 9, Figure 6 ) was successfully synthesized [46] . It has been demonstrated that DNA polymerase can recognize BTTP as a substrate and the boronic acid-labeled DNA as a template, which are critical issues for aptamer selection work. One challenging task of carbohydrate recognition is the differentiation of glycosylation patterns of a glycoprotein. By taking advantage of the general aptamer selection method developed about 18 years by the labs of Szostak [315] , Joyce [316] , and Gold [317] , as well as the intrinsic affinity of boronic acids for carbohydrates, it is reasonable to believe that incorporation of a boronic acid into the DNA aptamer would allow for the selection process to gravitate toward the glycosylation site and therefore allow for differentiation of glycosylation patterns. Anslyn and co-workers invented a method of using aptamers to fine-tune the selectivity of boronic acid-based synthetic small molecule receptors [240] . Specifically, organic receptor 10 (Figure 7 ) was immobilized on glyoxal agarose beads through reductive amination to form immobilized receptor 11, which was in complexation with tartrate as the target for the selection. Control compound 12, incapable of binding tartrate, was used for counter selection. The progress of the selection was monitored by incorporating a radiolabel into the RNA pool. By this approach, the author successfully selected an aptamer with good selectivity for the complex between bis-boronic acid receptor 11 and tartrate (>14 for tartrate, K d = 2.1 × 10 −4 M and K d < 3 × 10 −3 M for citrate in 20% MeOH). One explanation for the selectivity is that aptamer might form a pocket more precisely to accommodate the receptor-tartrate complex, while excluding citrate via steric interactions or charge repulsion. This work can lead to the applications for improving the specificity of synthetic receptors and the development of biosensors for small organic analytes.

In addition to nucleic acid-based boronolectins (NABL), there have been efforts in making peptide boronolectins (PBL) for the same purpose [241] [242] [243] [244] . For examples, the Anslyn lab group developed a chemosensor array of PBL for saccharides, saccharide derivatives, and even sucralose in a real world beverage sample with good water solubility and high sensitivity at physiological pH [241] . The Duggan lab prepared solid-supported PBL derived from 4-borono-Lphenylalanine and studied their affinity for alizarin [242] . The Hall lab developed a general solid-phase approach to the synthesis and isolation of functionalized boronic acids, which should be very useful in combinatorial library synthesis of boronic acid-based carbohydrate sensors [243] . The Lavigne lab reported their PBL sensors for glycomics recognition with the potential for cancer diagnosis [244] . Along a similar line, Hall and coworkers have also established a prototypic bead-supported split-pool library of triamine-derived triboronic acid receptors [318] .

Recently, the Schultz lab successfully demonstrated the feasibility of adding the boronate functionality to the genetic code of E. coli in high yield and efficiency [155, 156] . Specifically, p-boronophenylalanine (13, Figure 8 ) was incorporated into proteins. The intrinsic affinity of the boronic acid group allows for the selection of high affinity PrBL. In addition, this method has the potential to be used for purifycation of native protein sequences in a one-step scarless affinity procedure.

Recently, the Bertozzi lab has developed labeling approaches to probing the functions of glycans in living system and application of these tools to studies of glycobiology such as the identification of novel glycan-based tumor biomarkers [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] .

The general principle relies on the availability of a toolkit of "azido sugars" for metabolically labeling different classes of glycans. These azido sugars can be recognized by their respective processing/incorporation enzymes and can be used for tagging via two bio-orthogonal reactions: Staudinger ligation (Figure 9 ) and [2+3] cycloaddition (click reaction) (Figure 10 ) [335] [336] [337] . Along this line, a series of successful applications have been published [320, 323, 325, 330, 332, 334] . For examples, the azide-bearing ManNAz has been employed to visualize sialic acids in live cells using phosphine and cyclooctyne reagents [320, 334] ; the same strategy was further developed to perform in vivo imaging [332] ; simultaneous imaging of the expression of two different glycans was also achieved by introducing two chemical reporters (ketone and azide) into sialic acid and N-acetylgalactosamine (GalNAc) residues, which allowed controlled introduction of two fluorescent probes to monitor glycan expression and dynamics [323] ; and a FRET-based fluorogenic phosphine for live-cell imaging with Staudinger ligation was also exploited recently [325] .

In using the Huisgen [3+2] dipolar cycloaddition with alkynes, the Bertozzi lab developed strained alkynes (14 and 15, Figure 10 ) for copper-free cycloaddition [320, 322, 324, 326, 328] . The Boons lab subsequently also reported their own strained alkynes for copper-free cycloaddition with azido compounds (16, Figure 10 ) [338] . The availability of such alkynes for copper free cycloaddition is especially important in live cell imaging because of the toxicity issues of copper in living systems. With this technique, the dynamics of glycan trafficking and a population of sialoglycoconjugates with unexpectedly rapid internalization kinetics were studied. In another example, 14 was used for the noninvasive imaging of glycans in live developing zebrafish [327] . In this experiment, zebrafish embryos were first treated with an unnatural sugar to metabolically label their cell-surface glycans with azides and then visualized by using an in vivo Cu-free click reaction with fluorophoreconjugated 14. The Bertozzi group also performed a spatiotemporal analysis of glycan expression and trafficking and identified patterns by using a multicolor detection strategy [324] .

In conclusion, carbohydrates serve very important biological functions in a wide variety of processes. "Binders" that can specifically recognize a carbohydrate biomarker can be used for site specific delivery of therapeutic and imaging agents. Specific recognition of carbohydrates that mediate pathological processes has the potential to be used as a way to develop novel types of therapeutic agents. Recent years have seen a tremendous amount of work in developing carbohydrate "binders," with boronolectins showing special promises. It is almost a certainty that new diagnostic and therapeutic agents will come out in the not too distant future that rely on carbohydrate recognition. 

Selective carbohydrate recognition by synthetic receptors in aqueous solution

Fluorescent chemosensors for carbohydrates: a decade's worth of bright spies for saccharides in review

Boronic acid-based sensors for carbohydrates

Boronolectins and fluorescent boronolectins-an examination of the detailed chemistry issues important for their design

Cell surface carbohydrates in hematopoietic cell differentiation and malignancy

Cell Surface Carbohydrates and Cell Development

Cell surface carbohydrates: cell-type specific expression

Possible roles of tumor-associated carbohydrate antigens

Tn pancarcinoma markers-autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast-carcinoma immunotherapy

Sialyl Lewis X-dependent lung colonization of B16 melanoma cells through a selectin-like endothelial receptor distinct from E-or P-selectin

Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells

Serum sialyl Lewis X and cytokeratin 19 fragment as a predictive factors for recurrence in patients with stage I non-small cell lung cancer

Significance of carbohydrate antigen sialyl-Lewis X, sialyl-Lewis A, and possible unknown ligands to adhesion of human urothelial cancer cells to activated endothelium

Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-the warburg effect revisited

Regulation of signal transduction pathways in development by glycosylation

Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA

Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer

Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer

Characterization of a prostate carcinoma mucin-like antigen (PMA)

Mucins and mucin binding proteins in colorectal cancer

Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells

The pattern of glycosyl-and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans

Glycoprotein glycosylation and cancer progression

Cell surface N-acetylneuraminic acid alpha 2,3-galactoside-dependent intercellular adhesion of human colon cancer cells

Harnessing changes in cellular glycosylation in new cancer treatment strategies

Increased tumorigenicity of rat colon carcinoma cells after alpha 1,2-fucosyltransferase FTA anti-sense cdna transfection

Sialyl Lewis(x) antigen as defined by monoclonal antibody AM-3. Is a marker of dysplasia in the colonic adenoma-carcinoma sequence?

MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinomaassociated alterations of O-glycosylation

Ah, sweet mystery of death! Galectins and control of cell fate

A serum glycomics approach to breast cancer biomarkers

Tk a new colon tumor-associated antigen resulting from altered O-glycosylation

Clinical applications of glycomic approaches for the detection of cancer and other diseases

Increased alpha 2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma

Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells

Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125

N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis

Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum

Changes in the fucose content of haptoglobin in breast and ovarian cancer: association with disease progression

Carbohydrate structure and differential binding of prostate specific antigen to maackia amurensis lectin between prostate cancer and benign prostate hypertrophy

Alterations in the serum glycome due to metastatic prostate cancer

Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins

Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples

Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells

Ribonucleases expressed by human pancreatic adenocarcinoma cell lines

Specific measurement of O-linked core 2 sugar-containing isoforms of hyperglycosylated human chorionic gonadotropin by antibody b152

Hyperglycosylated hCG

Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach

Structures of disease-specific serum alpha-fetoprotein isoforms

In the influenza viruses: influenza virus neuraminidase, enzyme and antigen

Selection and characterization of a neuraminidaseminus mutant of influenza virus and its rescue by cloned neuraminidase genes

Neuraminidase inhibitors and their role in avian and pandemic influenza

Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens

HIV entry and its inhibition

CancerLectinDB: a database of lectins relevant to cancer

Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope

Targeting the glycans of gp120: a novel approach aimed at the achilles heel of HIV

Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120

HIV-inhibitory natural products part 71-cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner

A potent novel anti-HIV protein from the cultured cyanobacterium scytonema varium

The D-mannose-specific lectin from gerardia savaglia blocks binding of human immunodeficiency virus type I to H9 cells and human lymphocytes in vitro

The capsule is a virulence determinant in the pathogenesis of pasteurella multocida M1404 (B:2)

Lipopolysaccharide endotoxins

Signature-tagged mutagenesis of pasteurella multocida identifies mutants displaying differential virulence characteristics in mice and chickens

Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids

Pseudomonas aeruginosa and pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2)

The pili of pseudomonas aeruginosa strains PAK and PAO bind specifically to the carbohydrate sequence beta GalNAc(1-4)beta Gal found in glycosphingolipids asialo-GM1 and asialo-GM2

Adherence of pseudomonas aeruginosa and candida albicans to glycosphingolipid (asialo-GM1) receptors is achieved by a conserved receptor-binding domain present on their adhesins

Lacto-and ganglio-series glycolipids are adhesion receptor for neisseria gonorrhoeae

Interactions between glycoconjugates from human respiratory airways and pseudomonas aeruginosa

44) to the Kauffmann-White scheme

Glycosylation in the control of selectin counter-receptor structure and function

Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites

ABO blood group and related antigens, natural antibodies and transplantation

ABO blood group system: ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes

Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation

Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies

Gal Knockout pigs: any more carbohydrates? Transplantation

Gal knockout and beyond

The alpha-gal epitope and the anti-gal antibody in xenotransplantation and in cancer immunotherapy

Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells

Human embryonic stem cells reprogram myeloid precursors following cell-cell fusion

Glycan stem-cell markers are specifically expressed by spermatogonia in the adult non-human primate testis

Aptamer-based strategies for stem cell research

The glycans of stem cells

Carbohydrate antigens expressed on stem cells and early embryonic cells

LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal

Cell-surface enrichment of fucosylated glycoconjugates in the 8-to 16-cell mouse embryo

Chick Embryo metanephros: the glycosylation pattern as revealed with lectin conjugates. Acta Histochem

Changes in protein glycosylation during chick embryo development

Change in glycosylation of chicken transferrin glycans biosynthesized during embryogenesis and primary culture of embryo hepatocytes

Cell surface biomarkers of embryonic stem cells

In vitro selection of rna aptamers that bind to cell adhesion receptors of trypanosoma cruzi and inhibit cell invasion

In vitro selection and affinity function of the aptamers to bacillus anthracis spores by SELEX

Gold LA Tenascin-C aptamer identified by tumor cell selex: systematic evolution of ligands by exponential enrichment

Single-stranded dna aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment

Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase

Identification of liver cancer-specific aptamers using whole live cells

Aptamers generated by cell Selex for biomarker discovery

Aptamers evolved from live cells as effective molecular probes for cancer study

Protein evolution with an expanded genetic code

A genetically encoded boronate-containing amino acid

Signal Transduction through glyco(sphingo)lipids -introduction and recent studies on glyco (sphingo) lipid-enriched microdomains

Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains

Glycosynapses: microdomains controlling carbohydratedependent cell adhesion and signaling

GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells

Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to lyso-GM3

Dynamic Interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription

Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling

Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes

Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta-post-translational regulation of turnover and transactivation Activity

NFkappaB Activation is associated with its O-GlcNAcylation state under hyperglycemic conditions

Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase

The O-linked N-acetylglucosamine modification in cellular signalling and the immune system. Protein modifications: beyond the usual suspects' review series

A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin

O-glycosylation of Sp1 and transcriptional regulation of the calmodulin gene by insulin and glucagon

Beta-D-glucosyl-hydroxymethyluracil: a novel modified base present in the DNA of the parasitic protozoan T

Site-specific interactions of JBP with base and sugar moieties in duplex J-DNA. Evidence for both major and minor groove contacts

Recognition of base J in duplex DNA by J-binding protein

Beta-D-glucosyl-hydroxymethyluracil, a novel base in african trypanosomes and other kinetoplastida

The modified base J is the target for a novel dna-binding protein in kinetoplastid protozoans

Discovery, biosynthesis, and possible functions

Regulation of trypanosome DNA glycosylation by a SWI2/SNF2-like protein

JBP2, a SWI2/SNF2-like protein, regulates de novo telomeric dna glycosylation in bloodstream form trypanosoma brucei

Glycated hemoglobin as a marker of cardiovascular risk

Assessing glycemic control with self-monitoring of blood glucose and hemoglobin-A(1c) measurements

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) Trial

Perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease

Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes

Is it possible to reduce cardiovascular risk with glucoselowering approaches?

Products of condensation between glucsoe and p-phenetidine

Review Article The immunology and immunotherapy of breast cancer: an update

Chemistry of browning reactions in model systems

Nanoscale processing of polyaniline and phthalocyanines for sensing applications

Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation

The past decade: fibrinogen

Fibrinogen and fibrin structure and functions

Carbohydrate structure of human fibrinogen. use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides

Amino acid sequence of the beta chain of human fibrinogen

Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma')

The role of the carbohydrate moiety in the biologic properties of fibrinogen

γ-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the g-chain of human fibrinogen

Study of carbohydrate release during the clotting of fibrinogen

The release of carbohydrate moieties from human fibrinogen by almond glycopeptidase without alteration in fibrinogen clottability

Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns

Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers

The ashwell receptor mitigates the lethal coagulopathy of sepsis

Increased carbohydrate content of the fibrinogen molecule

Fibrinogen lima: a homozygous dysfibrinogen with an a alpha-arginine-141 to serine substitution associated with extra N-glycosylation at a alpha-asparagine-139. impaired fibrin Gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator

Fibrinogen kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization

Pancreatic cancer and fibrinogen storage disease

Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients

Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis

Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis

Fibrinogen induces IL-8 synthesis in human neutrophils stimulated with formyl-methionylleucyl-phenylalanine or leukotriene B(4)

Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor

Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity

Fibrinogen assembly, secretion, and deposition into extracellular matrix by mcf-7 human breast carcinoma cells

Tumors and fibrinogen. the role of fibrinogen as an extracellular matrix protein

Fibrinogen and tumor cell metastasis. Haemostasis

Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells

Fibrinogen and its fragment D stimulate proliferation of human hemopoietic cells in vitro

Role of fibrinogen-and platelet-mediated hemostasis in mouse embryogenesis and reproduction

Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of GammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism

Fibrinogen philadelphia, a hypodysfibrinogenemia characterized by abnormal polymerization and fibrinogen hypercatabolism due to Gamma S378P mutation

Fibrinogen montreal. A new case of congenital dysfibrinogenemia with defective aggregation of monomers

A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization

Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules

Louis: a new inherited fibrinogen variant, coincidentally associated with hemophilia A

Fibrinogen troyes: fibrinogen metz. two new cases of congenital dysfibrinogenemia

Fibrinogen niigata with impaired fibrin assembly: an inherited dysfibrinogen with a Bbeta Asn-160 to Ser substitution associated with extra glycosylation at Bbeta Asn-158

Structural alterations in hereditary dysfibrinogens

A novel variant fibrinogen, deletion of Bbeta111Ser in coiled-coil region, affecting fibrin lateral aggregation

Intracranial hemorrhage as the initial manifestation of a congenital disorder of glycosylation

Investigation of sugar-binding sites in ternary ligand-copper(II)-carbohydrate complexes

Boronic acid compounds as potential pharmaceutical agents

Artificial Receptors for Chemical Sensors

Biologically active boronic acid compounds

Robust immune responses elicited by a fully synthetic three-component vaccine

Microscopy Handbooks). 1 ed. Oxford UK: Garland Science

Handbook of Animal Lectins: Preperties and Biomedical Applications

Handbook of Plant Lectins: Properties and Biological applicaions

Artificial receptors as chemosensors for carbohydrates

Tuning the specificity of a synthetic receptor using a selected nucleic acid receptor

Boronic acid based peptidic receptors for pattern-based saccharide sensing in neutral aqueous media, an application in real-life samples

Remarkably selective saccharide recognition by solid-supported peptide boronic acids

Modular solid-phase synthetic approach to optimize structural and electronic properties of oligoboronic acid receptors and sensor for the aqueous recognition of oligosaccharides

Peptide borono lectins (PBLs): a new tool for glycomics and cancer diagnostics

A tricyclic polyamide receptor for carbohydrates in organic media

Highly selective disaccharide recognition by a tricyclic octaamide cage

Carbohydrate recognition in water by a tricyclic polyamide receptor

A synthetic lectin analog for biomimetic disaccharide recognition

A synthetic lectin for O-linked beta-N-acetylglucosamine

Photonic crystal carbohydrate sensors: low ionic strength sugar sensing

A fluorescent glucose sensor binding covalently to all five hydroxy groups of α-d-glucose. A reinvestigation

A new glucose-selective fluorescent bisboronic acid. first report of strong α-furanose complexation in aqueous solution at physiological pH

Novel saccharidephotoinduced electron transfer sensors based on the interaction of boronic acid and amine

The first fluorescent diboronic acid sensor specific for hepatocellular carcinoma cells expressing sialyl Lewis X

Fluorescent chemosensors of carbohydrates. a means of chemically communicating the binding of polyols in water based on chelation-enhanced quenching

Anion sensing using quinolinium based boronic acid probes

A colorim etric sensor array for detection and identification of sugar

Recent development of anion selective fluorescent chemosensors

Boronic acid based probes for microdetermination of saccharides and glycosylated biomolecules

Fluorescence-based glucose sensors

Evidence for mono-and bisdentate boronate complexes of glucose in the furanose form. application of 1 J C-C coupling constants as a structural probe

Alizarin red as a general fluorescent reporter for studying the binding of boronic acids and carbohydrates

The relationship among pK a , pH, and binding constants in the interactions between boronic acids and diols-it is not as simple as it appears

Oxazaborolidine derivatives inducing autoinducer-2 signal transduction in vibrio harveyi

Oxazaborolidines as asymmetric inducers for the reduction of ketones and ketimines

Synthesis and evaluation of oxazaborolidines for antibacterial activity against streptococcus mutans

α-Amino acid chelative complexation by an arylboronic acid

Boronic acid-based bipyridinium salts as tunable receptors for monosaccharides and alpha-hydroxycarboxylates

Boronic acid receptors for X-hydroxycarboxlates: high affinity of shinkai's glucose receptor for tartrate

A new saccharide sensor based on a tetrathiafulvalene-anthracene dyad with a boronic acid group

pKa Valuaes and geometries of secondary and tertiary amines complexed to boronic acids-implications for sensor design

An improved class of sugar-binding boronic acids, soluble and capable of complexing glycosides in neutral water

Aminophosphonic and aminoboronic acids as key elements of a transition state analogue inhibitor of enzymes

Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid

Development of the proteasome inhihitor veleade((TM)) (Bortezomib). Can Invest

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro

Ringe D. 2.4 Angstrom resolution crystal structure of the prototypical hormone-processing protease Kex2 in complex with an Ala-Lys-Arg boronic acid inhibitor

Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase -IV -identifycation of a cyclic species containing a B-N bond

Effect of benzene boronic acids on sporulation and on production of enzymes in bacillus subtilis cells. Spores VI

Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20s proteasome

X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (novo). a model for the catalytic transition state

The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase

Structure-based approach for binding site identification on AmpC beta-lactamase

Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin carlsberg complexes

Observation of tightly bound boron-11 nuclear magnetic resonance signals on serine proteases. direct solution evidence for tetrahedral geometry around the boron in the putative transition-state analogs

Structural analysis of specificity: a-Lytic protease complexes with analogues of reaction intermediates

Excitation and emission wavelength ratiometric cyanide-sensitive probes for physiological sensing

Cyanide-sensitive fluorescent probes. Dyes Pigments

A wavelength-ratiometric fluoridesensitive probe based on the quinolinium nucleus and boronic acid moiety

New sensitive and selective fluorescent probes for fluoride using boronic acids

Nitro-substituted stilbeneboronate pinacol esters and their fluoro-adducts. fluoride ion induced polarity enhancement of arylboronate esters

A new fluorescein derivative bearing a boronic acid group as a fluorescent chemosensor for fluoride Ion

Selective fluorescence detection of fluoride using boronic acids

Carbohydrate recognition by boronolectins, small molecules, and lectins

A detailed examination of boronic acid-diol complexation

Novel type of fluorescent boronic acid for carbohydrate recognition

Design, synthesis and evaluation of efflux substrate-metal chelator conjugates as potential anti-microbial agents

A unique quinolineboronic acid-based supramolecular structure that relies on double intermolecular B-N bonds for self-assembly in solid state and in solution

Effect of extended conjugation with a phenylethynyl group on the fluorescence properties of watersoluble arylboronic acids

Synthesis, evaluation, and computational studies of naphthalimide-based long-wavelength fluorescent boronic acid reporters

Identification of the first fluorescent alpha-amidoboronic acids that change fluorescent properties upon sugar binding

3,6-Disubstituted carbazole-based bisboronic acids with unusual fluorescence transduction as enantioselective fluorescent chemosensors for tartaric acid

Boronic acid-linked fluorescent and colorimetric probes for copper ions

Boronic acid-based fluorescent receptors for selective recognition of thymine glycol

Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: structure and selectivity of complex formation

Highly efficient fluorescent sensing for alpha-hydroxy acids with c-3-symmetric boronic acid-based receptors

Chiral mono boronic acid as fluorescent enantioselective sensor for mono alpha-hydroxyl carboxylic acids

6,6'-Bis-substituted BINOL boronic acids as enantio selective and chemoselective fluorescent chemosensors for D-sorbitol

Synthesis and evaluation of dual wavelength fluorescent benzo[b]thiophene boronic acid derivatives for sugar sensing

A fluorescent sensor array for saccharides based on boronic acid appended bipyridinium salts

Highly water-soluble monoboronic acid probes that show optical sensitivity to glucose based on 4-sulfo-1,8-naphthalic anhydride

Diboronic acids as fluorescent probes for cells expressing sialyl Lewis X

Assessing the terminal glycosylation of a glycoprotein by the naked eye

In vitro selection of rna molecules that bind specific ligands

Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA

Systematic Evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

Synthesis, decoding, and preliminary screening of a bead-supported split-pool library of triboronic acid receptors for complex oligosaccharides

A comparative study of bioorthogonal reactions with azides

A strain-promoted [3+2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems

Bioorthogonal click chemistry: covalent labeling in living systems

Copper-free click chemistry for dynamic in vivo imaging

Imaging cell surface glycans with bioorthogonal chemical reporters

Second-generation difluorinated cyclooctynes for copper-free click chemistry

A FRET-based fluorogenic phosphine for live-cell imaging with the staudinger ligation

Metabolic labeling of glycans with azido sugars for visualization and glycoproteomics

In vivo imaging of membrane-associated glycans in developing zebrafish

Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via staudinger ligation

Imaging the glycome

Chemistry in living systems

Chemical technologies for probing glycans

Chemical remodelling of cell surfaces in living animals

A chemical reporter strategy to probe glycoprotein fucosylation

Cell surface engineering by a modified staudinger reaction

Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks

Cu-catalyzed azide-alkyne cycloaddition

1.3-dipolar cycloadditions. Past and future

Visualizing metabolically labeled glycoconjugates of living cells by copper-free and fast huisgen cycloadditions